03rd week of 2010 patent applcation highlights part 37 |
Patent application number | Title | Published |
20100015082 | Compositions For Forming Long Wear Cosmetic Products - A color cosmetic composition containing at least one ester of rosin acid, polyglyceryl-2 isostearate/dimer dilinoleate copolymer, and pigments or colorants. | 2010-01-21 |
20100015083 | Method of producing pvp/fullerene complex and aqueous solution thereof - An aromatic hydrocarbon solution of a fullerene or a fullerene mixture is mixed with an ethanol solution of polyvinylpyrrolidone (PVP), water is added to the mixed solution, the solvent is removed and then an aqueous solution of a complex of a fullerene or a fullerene mixture with polyvinylpyrrolidone (PVP) is obtained. Under a condition free from a halogen, a PVP/fullerene complex excellent in manifestation of fullerene properties, stability and safety and an aqueous solution thereof are obtained. | 2010-01-21 |
20100015084 | Compounds for Treating Papilloma Virus Infection - The present invention relates to polyamide compositions and therapies for treating cells infected with papilloma virus. | 2010-01-21 |
20100015085 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION/INFECTION, APOPTOSIS AND STRESS - Disclosed herein are novel compounds, their use in the treatment and prevention of joint and/or cartilage inflammation that provide an alternative to the NSAIDS and selective COX-2 inhibitors by activating endogenous detoxifying cellular defense mechanisms that act to neutralize toxic cellular intermediate. These compounds are PPAR-alpha agonists and/or phase 2 gene activators. | 2010-01-21 |
20100015086 | USE OF IL-22 FOR THE TREATMENT OF CONDITIONS OF METABOLIC DISORDERS - The use of IL-22 for the treatment of metabolic disorders including hyperlipidemia, obesity, hyperinsulinemia and diabetics. IL-22 may also be used in combination with insulin for diabetics. | 2010-01-21 |
20100015087 | HIV-1 TAT, OR DERIVATIVES THEREOF FOR PROPHYLACTIC AND THERAPEUTIC VACCINATION - The present invention refers to Tat as the active principle for a prophylactic and/or therapeutic vaccine against HIV infection, the progression towards AIDS and the development of tumors and other syndromes and symptoms in subjects infected by HIV. Tat is in biologically active form either as recombinant protein or peptide or as DNA. More particularly, the invention refers to a vaccine based on HIV-1 Tat as immunogen, inoculated as DNA and/or recombinant protein or as peptides, alone or in combination with other genes or viral gene products (Nef, Rev, Gag) or parts thereof, or in combination with various immuno-modulant cytokines (IL-12, IL-15) or with the gene coding for an immuno-modulant cytokine or part thereof. Tat, Nef, Rev, Gag and the immuno-modulant cytokines are administrated both as a mixture of recombinant proteins, peptides or fusion proteins (Tat/Nef, Tat/Rev, Tat/Gag, Tat/IL-12, Tat/IL-15) or as plasmid DNA. | 2010-01-21 |
20100015088 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS - The present invention provides delivery agent compounds, compositions containing delivery agent compounds and an active agent and methods for delivering active agents, such as biologically or chemically active agents. | 2010-01-21 |
20100015089 | HETERODIMERIC FUSION PROTEINS USEFUL FOR TARGETED IMMUNE THERAPY AND GENERAL IMMUNE STIMULATION - Disclosed are methods for producing fusion proteins with the heterodimeric cytokine, interleukin-12. In order to insure that the proper ratio of fused and non-fused subunits are obtained in the fusion protein, a specific stepwise approach to genetic engineering is used. This consists of first expressing the non-fused p40 IL-12 subunit in a production cell line, followed by or simultaneously expressing in the same cell, a second recombinant fusion protein consisting of the fused polypeptide linked by a peptide bond to the p35 subunit of IL-12. Molecules containing the p35 fusion protein cannot be secreted from the transfected mammalian cell without first complexing in a one to one ratio with the p40 subunit, thus ensuring the production of active heterodimeric fusion proteins. | 2010-01-21 |
20100015090 | Combinations for HCV Treatment - The present invention relates to co-administering a Hepatitis C virus NS3/4A protease inhibitor and a cytochrome P450 monooxygenase inhibitor. The combination acts by interfering with the life cycle of the hepatitis C virus and is therefore useful as an antiviral therapy. As such, the combination may be used for treating or preventing Hepatitis C infections in patients. The invention also relates to compositions comprising the combination of inhibitors. The invention also relates to kits and pharmaceutical packs comprising a Hepatitis C virus NS3/4A protease inhibitor and a cytochrome P450 monooxygenase inhibitor. The invention also relates to processes for preparing these compositions, combinations, kits, and packs. | 2010-01-21 |
20100015091 | MODIFIED STAT1 TRANSGENE THAT CONFERS INTERFERON HYPERRESPONSIVENESS, METHODS AND USES THEREFOR - Methods of enhancing cellular responses to interferons are disclosed. These methods comprise administering to a subject a vector comprising a Stat1-CC transgene, such as an AAV5 vector comprising a reporter operably linked to a nucleic acid sequence encoding a Stat1-CC polypeptide. The methods can be used in the treatment of diseases that involve interferon responses, such as multiple sclerosis, amyotrophic lateral sclerosis, and lupus; viral infections such as infection by hepatitis C virus, influenza A virus, cowpox virus, Sendai virus or Encephalomyocarditis virus; respiratory disorders; and cancers. | 2010-01-21 |
20100015092 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 2010-01-21 |
20100015093 | Methods and compositions of treating a flaviviridae family viral infection - Briefly described, embodiments of this disclosure include compounds, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of inhibiting HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3′UTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like. | 2010-01-21 |
20100015094 | ANTIVIRAL NUCLEOSIDE ANALOGS - The invention provides compounds of Formula (I), as described herein, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates that are useful for preparing the compounds. The compounds of Formula (I) are useful as anti-viral agents and/or as anti-cancer agents. | 2010-01-21 |
20100015095 | RESTORATION OF VISUAL RESPONSES BY IN VIVO DELIVERY OF RHODOPSIN NUCLEIC ACIDS - Nucleic acid vectors encoding light-gated cation-selective membrane channels, in particular channelrhodopsin-2 (Chop2), converted inner retinal neurons to photosensitive cells in photoreceptor-degenerated retina in an animal model. Such treatment restored visual perception and various aspects of vision. A method of restoring light sensitivity to a retina of a subject suffering from vision loss due to photoreceptor degeneration, as in retinitis pigmentosa or macular degeneration, is provided. The method comprises delivering to the subject by intravitreal or subretinal injection, the above nucleic acid vector which comprises an open reading frame encoding a rhodopsin, to which is operatively linked a promoter and transcriptional regulatory sequences, so that the nucleic acid is expressed in inner retinal neurons. These cells, normally light-insensitive, are converted to a light-sensitive state and transmit visual information to the brain, compensating for the loss, and leading to restoration of various visual capabilities. | 2010-01-21 |
20100015096 | Fusion Proteins of Mycobacterium Tuberculosis - The present invention relates to compositions and fusion proteins containing at least two | 2010-01-21 |
20100015097 | METHOD OF MAKING SORBENT, THE SORBENT OBTAINED BY THIS METHOD AND THE USES OF THE SORBENT AS FEED ADDITIVE AND MEDICINE - The present invention relates to a method of making a sorbent, comprising the steeps of crushing seed husks, acid hydrolysis with extraction of water-soluble ballast substances and formation of the target composition of lignin, cellulose and melanin, water rinsing and drying, wherein the acid hydrolysis is made with an 0.1-36% acid solution during 0.3-4.5 hours in the boiling mode under pressure in the range 0.1-0.7 MPa, rinsing is made with water and/or a 0.1-1.0% alkali solution and then softened water, and the product is subsequently dried. The sorbent comprises a porous multilevel matrix on the basis of lignin, cellulose and melanin. The invention further discloses the sorbent and its uses as for prophylaxis and treatment of toxicoses, free-radical pathologies, diarrhea syndromes which are caused by ecotoxicants, viral and bacterial infections, for prophylactic and treatment of animal diseases caused by mycotoxins, pesticides, bad-quality forages in all kinds of animals. | 2010-01-21 |
20100015098 | ISOLATED PHAGES AND THEIR USE IN FOOD OR PET FOOD PRODUCTS - The present invention relates to phage isolates having a strong lytic activity against pathogenic Enterobacteriaceae such as | 2010-01-21 |
20100015099 | Materials and methods relating to treatment of injury and disease to the central nervous system - The application provides materials and methods for promoting myelination of neuronal axons in the CNS. These derive from the findings first that the molecules Nogo and Caspr interact with one another during establishment and maintenance of the axoglial junction, and secondly that the molecules F3 and NB-3 are capable of promoting oligodendrocyte maturation via interaction with Notch. The materials and methods provided may be used in the treatment of CNS damage, in particular the treatment of spinal cord injury, multiple sclerosis, epilepsy and stroke. | 2010-01-21 |
20100015100 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS - The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides an improved method for the formation of pancreatic endoderm, pancreatic hormone expressing cells and pancreatic hormone secreting cells. The present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer. | 2010-01-21 |
20100015101 | NOVEL TUMOR ANTIGEN PEPTIDES - The invention relates to novel tumor antigen proteins and peptides derived therefrom and use of the same in the filed of cancer immunity. Specifically, the inventions relates to a peptide which comprises a partial peptide derived from Lengsin, BJ-TSA-9, C20orf42, BUB1, C10orf3 or HIFPH3 and is capable of binding to an HLA antigen and is recognized by a CTL, and a pharmaceutical composition comprising the peptide and a pharmaceutically acceptable carrier. | 2010-01-21 |
20100015102 | Composition for treatment of cartilage disease - The present invention provides a composition for regenerating cartilage or treating a cartilage disease containing a monovalent metal salt of alginic acid for which the endotoxin level thereof has been lowered to an extent that does not substantially induce inflammation or fever. As a result, it is possible to provide a composition for regenerating cartilage that improves cartilage regenerative action and ease of application to a cartilage injury lesion, and a composition for treating a cartilage disease, which has the effects of protecting cartilage from mechanical irritation, inhibiting degenerative changes in cartilage caused by wear and inflammation, repairing a cartilage injury lesion, and inhibiting inflammation and pain of joint tissue. | 2010-01-21 |
20100015103 | Cell culture method and application thereof - The invention relates to a cell culture method, particularly to a co-culture method for human mesenchymal stem cells and target animal cells, in order to solve the problem that animal cells are not easy to survive alone upon culturing. The invention also provides a method for using a stem cell conditioned medium to culture animal cells. The invention also provides a method to induce the transformation of human fetal islet-like cell clusters from human stem cells and its application thereof. | 2010-01-21 |
20100015104 | GENERATION OF ADIPOSE TISSUE AND ADIPOCYTES - The invention provides novel methods by which adipose tissue, preadipocytes, and adipocytes can be generated for research purposes, and methods for identifying cell populations that can proliferate and differentiate into adipocytes in vivo. The invention further provides a means for the in vivo derivation of “designer” or “customized” adipose tissue, preadipocytes, and adipocytes. Also provided are methods for identifying agents that affect adipocytes and adipose tissue, as well as the agents themselves. In particular, the present invention allows for creation of tissues and cells that can be used to screen for agents useful for treating human disorders associated with adipose tissue, including obesity, metabolic syndrome, and diabetes. | 2010-01-21 |
20100015105 | METHOD OF TREATING SCHIZOPHRENIA - A method of treating schizophrenia in a subject in need thereof is provided. The method comprising, administering to the subject a therapeutically effective amount of cells expressing at least one exogenous polypeptide forming a connexin channel and/or a hyperpolarizing ion channel, thereby treating the schizophrenia in the subject. | 2010-01-21 |
20100015106 | Method and compositions for inhibiting tumorigenesis - The present invention discloses methods of producing neuronal cells from stem cells, particularly from adult brain stem cells. The use of such neuronal cells in the treatment and/or prevention of neurological diseases, conditions and/or injuries is also disclosed. In addition, the present invention provides a novel source of neuronal cells for use as a laboratory tool. | 2010-01-21 |
20100015107 | Expression elements - The invention relates to genetic elements capable of improving the levels of expression of operably-linked transcription units. In particular, said genetic elements are derived from the 5′ untranslated regions of ribosomal protein genes and may comprise a CpG island. Also provided are vectors and host cells comprising said genetic elements and methods of use to obtain high levels of recombinant gene expression. | 2010-01-21 |
20100015108 | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA - Disclosed are cells and methods for treating or preventing tumor formation or infections with pathogens in a patient. The cells of the invention are antigen-presenting cells (e.g., dendritic cells or macrophage) that have been loaded with RNA derived from tumors or pathogens. By administering the RNA-loaded antigen-presenting cells to a patient, tumor formation or pathogen infections can be treated or prevented. Alternatively, the RNA-loaded cells can be used as stimulator cells in the ex vivo expansion of CTL. Such CTL can then be used in a variation of conventional adoptive immunotherapy techniques. | 2010-01-21 |
20100015109 | Composition for High-ORAC Value Dietary Supplement - A dietary supplement composition having an ORAC value in excess of at least about 2,500 and which can be readily consumed in a small quantity is provided for supplementing an individual's daily intake. The dietary supplement composition suitably includes organic and/or vegan ingredients and can be consumed in quantities of as little as about 1 tablespoon to provide an amount of antioxidants equivalent to at least the minimum recommended daily intake of five to nine servings of fruits and/or vegetables. | 2010-01-21 |
20100015110 | FERMENTED MILK FOR SKIN IMPROVEMENT AND/OR TREATMENT AND PROCESS FOR PRODUCING THE SAME - The present invention provides a composition and fermented milk, which is derived from natural product, is highly safe, exhibits improvement effect and/or therapeutic effect on skin, and comprises fermented lactic acid bacteria excellent in manufacturability. Disclosed are: use of | 2010-01-21 |
20100015111 | Methods And Kits For The Treatment Inhibition, And Maintenance Of Gastrointestinal Disorders - The present invention comprises methods and kits that are useful treatment, inhibition and or maintenance of gastrointestinal disorders including inflammatory bowel disorder. The methods comprise: commencing treatment by orally administering a first dose of a pharmaceutical composition comprising from about 1 mg to about 8000 mg of an active agent and continuing said treatment, inhibition and or maintenance by orally administering an additional dose on a less than daily schedule of an active agent., either alone or in combination with a probiotic or optionally an antibiotic or optionally a prebiotic. | 2010-01-21 |
20100015112 | Methods for the Induction of Professional and Cytokine-Producing Regulatory T Cells - The field of the invention is generally related to methods used for the induction of T cells with suppressive activity. More specifically, the methods are used to generate professional regulatory T cells and cytokine-producing T cells with enhanced suppressive activity. | 2010-01-21 |
20100015113 | GP100-SPECIFIC T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein. | 2010-01-21 |
20100015114 | PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR EXPRESSION LEVEL AS AN INDEX OF ORGAN DAMAGE AND REGENERATION - The present invention relates to methods, reagents, and kits for assessing organ damage, such as damage due to ischemia reperfusion injury, in the course of a transplantation therapy and/or for assessing organ regeneration following transplantation therapy. The invention provides a method for determining an index of organ health in the course of transplantation therapy comprising measuring the expression level of peripheral-type benzodiazepine receptor (PBR) in the organ. Measuring the expression level of PBR is also useful for assessing the progress of organ regeneration in the course of transplantation therapy by comparing the index of organ health. The expression level of PBR may be used as a predictor of the outcome of transplantation therapy. | 2010-01-21 |
20100015115 | COMPOUND PREPARATION FOR QUICKLY REDUCING OXIDATIVE STRESS AND PREPARATION OF THE SAME - The present invention discloses a compound preparation for quickly reducing oxidative stress, which contains small molecules and mineral trace elements that can remove or help removing free radicals, can regulate the function of endocrine and circulatory digestive system, as well as other components that can rebuild inner harmony. The compound preparation is in solid dosage form, preferably effervescent tablet or effervescent granules. The preparative method of the compound preparation is also disclosed. Animal experiment and clinical trial show that the invention has strong effect in reducing oxidative stress and disease prevention. | 2010-01-21 |
20100015116 | Designer Ubiquitin Ligases For Regulation Of Intracellular Pathogenic Proteins - The present invention relates to a designer or recombinant ubiquitin ligase molecule that includes a toxin binding domain that is specific for a toxin active fragment, wherein the toxin active fragment is an enzymatically active fragment of one or more toxins or toxin serotypes; and an E3-ligase domain that comprises an E3-ligase or polypeptide that facilitates E2-mediated ubiquitination of the toxin active fragment. In an embodiment, the composition further includes a delivery system that allow the designer ubiquitin ligase to enter the cell. The present invention further includes methods for treating an individual intoxicated with a toxin by administering the designer ubiquitin ligase of the present invention. | 2010-01-21 |
20100015117 | COMPOSITIONS AND METHODS FOR TARGETING A POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM - The invention provides a chimeric CNS targeting polypeptide having a BBB-receptor binding domain and a payload polypeptide domain. The chimeric CNS targeting polypeptide can have a BBB-receptor binding domain consisting of a receptor binding domain from ApoB, ApoE, aprotinin, lipoprotein lipase, PAI-1, pseudomonas exotoxin A, transferrin, α2-macroglobulin, insulin-like growth factor, insulin, or a functional fragment thereof. Nucleic acids encoding a chimeric CNS targeting polypeptide are also provided. Further provided is a method of delivering a polypeptide to the CNS of an individual. The method consists of administering to the individual an effective amount of a chimeric CNS targeting polypeptide, said chimeric CNS targeting polypeptide comprising a BBB-receptor binding domain and a payload polypeptide domain. The method also can deliver a polypeptide to the lysosomes of CNS cells. | 2010-01-21 |
20100015118 | SUPPLEMENT FORMULA TO PREVENT AND DETER MUSCLE TRAUMA AND METHOD OF USING SAME - A body supplement and method for improving blood flow, muscle chemistry and/or the oxygenation of muscles, said supplement including cinchona bark or quinine in the range of approximately 0.0010 grams and 4.0 grams per dosage. | 2010-01-21 |
20100015119 | EPITHELIUM-IMPROVING AGENT - It is intended to provide an epithelium improving agent which improves the epithelial functions of various organs and, therefore, is usable in growing melanin-pigmented hair, relieving inflammatory symptoms in gingivitis and paradentitis, treating and relieving cold syndrome and bronchial asthma and, moreover, restoring sexual sensibility. An epithelium improving agent which comprises coenzyme Q10, cysteine, vitamins A, C and E and a skin extract of a rabbit inoculated with a vaccinia virus as the main components. In the case of treating gingivitis, paradentitis, cold syndrome and bronchial asthma, loratadine is further added. To an epithelium improving agent which is to be used in stimulating hair growth or restoring sexual sensibility, liquid paraffin and a hydrophilic ointment is further added to give a cream. Thus, the above problem can be solved. | 2010-01-21 |
20100015120 | HYBRID PROTEIN THAT CONVERTS ARACHIDONIC ACID INTO PROSTACYCLIN - A recombinant 130-kDa protein is constructed by linking together human cyclooxygenase (COX) isoform-2 (COX-2) and prostacyclin synthase (PGIS), via a 10-20 amino acid residues of a transmembrane sequence. The engineered protein is expressed in cells, and adopts the functions of COX and PGIS, to continually convert arachidonic acid (AA) into prostaglandin G | 2010-01-21 |
20100015121 | INHIBITING GS-FDH TO MODULATE NO BIOACTIVITY - Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase. | 2010-01-21 |
20100015122 | CLONING OF HONEY BEE ALLERGEN - The present invention relates to a recombinant polypeptide capable of binding to IgE from subjects allergic to venom of an insect from the order Hymenoptera having a homology of more than 70% to the amino acid sequence of SEQ ID NO: 2, which is the honey bee allergen Api m3 (acid phosphatase). The invention further relates to nucleic acid encoding the polypeptide, expression vectors, host cells and methods of preparing the polypeptide, as well as diagnostic and pharmaceutical uses thereof. | 2010-01-21 |
20100015123 | NOVEL THROMBOLYTIC MOLECULES AND A PROCESS THEREFOR - New thrombolytic protein molecules such as recombinant staphylokinase or streptokinase, urokinase, tissue plasminogen activator and the like, and suitable variants thereof, for targeting to brain tissue or any other tissue by either fusing to, or by synthesizing the candidate thrombolytic molecule(s) with a protein sequence comprising a strong amphipathic alpha helix containing protein transduction domain. Thrombolytic protein molecule(s) so engineered with the protein transduction domain is useful for enhanced uptake of such protein thrombolytic molecule(s) across the cell membranes and tissues including the blood brain barrier and find their use in the treatment of vascular thrombosis including cerebrovascular disorders caused by cerebral thrombosis or cerebral haemorrhage when used a as a therapeutic. The design and processes for cloning, expression, purification and protein transduction of such proteins across cell membranes. | 2010-01-21 |
20100015124 | Modulation of epidermal growth factor heterodimer activity - Provided is a method for screening a plurality of compounds for an ability to bind to a heterodimer of EGFR and another ERBB family member. Also provided are compounds that bind to heterodimers of EGFR and another ERBB family member; and methods of using the identified compounds to suppress the growth of a tumor associated with EGFR heterodimer activity in a subject. | 2010-01-21 |
20100015125 | METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE MEMORY BY BLOCKING INTRAHEPATIC ACTIVATED T CELL DELETION - The present invention discloses a method of inhibiting CD8+ T cell deletion by the liver via the use of Toll-like receptor-4 inhibitors. Also disclosed are compositions of Toll-like receptor-4 inhibitors and either immunogenic agents or activated CD8+ T cells, which can be used to enhance secondary immune responses in normal and immunocompromised subjects. The administration of Toll-like receptor-4 inhibitors, alone or in combination with one or both of immunogenic agents or activated CD8+ T cells, to subjects to enhance secondary immune responses is also disclosed. | 2010-01-21 |
20100015126 | Methods of Binding of Cross-Beta Structures By Chaperones - The invention relates to the field of biochemistry, biophysical chemistry, molecular biology, structural biology, immunology, cellular biology and medicine. More in particular, the invention relates to the capability (or property) of chaperones to bind a crossbeta structure. Even more in particular, the invention relates to extracellular chaperones such as BiP, haptoglobin, hsp72 or clusterin. The present invention provides the insight that a chaperone molecule and more in specific an extra-cellular chaperone molecule (such as for example BiP, clusterin, hsp72 or haptoglobin) is capable of interacting with a crossbeta structure and/or a molecule comprising a crossbeta structure and/or a molecule comprising a crossbeta structure precursor. Based on this insight, the present inventors have developed multiple methods and means. | 2010-01-21 |
20100015127 | TREATMENT FOR DEMYELINATING DISEASE - The invention relates to a method of treatment or prophylaxis of demyelinating disease, in particular the neurodegenerative phase of demyelinating disease, which comprises administration of an acid sensing ion channel (ASIC) antagonist. The invention also relates to a pharmaceutical composition comprising an ASIC antagonist in combination with an additional therapeutic agent, in particular an anti-inflammatory or immunmodulatory agent. | 2010-01-21 |
20100015128 | GRP78 as a Predictor of Responsiveness to Therapeutic Agents - The present application provides methods for detecting, diagnosing, monitoring, predicting responsiveness to therapeutic agents and staging cancer. The present application provides methods and compositions useful for suppression of GRP78 expression or activity in cancer cells to overcome resistance of certain therapeutic agents. The present application also provides methods for predicting whether a subject with cancer is at risk for developing resistance to certain therapeutic agents. | 2010-01-21 |
20100015129 | Methods of using F-spondin as a biomarker for cartilage degenerative conditions and bone diseases - Methods for identifying subjects having, or at risk for developing, osteoarthritis or other cartilage degenerative conditions by measuring levels of expression of F-spondin are provided. Assays, kits and methods for determining and assaying the presence of F-spondin in individual patients are disclosed. Oligonucleotide probes and primers for use in the assays, kits and methods are described. Assays and methods are disclosed for identifying candidate compounds that modulate F-spondin levels of expression and/or function or for determining and evaluating an individual's response to drugs and therapeutic agents, are provided. The invention further relates to the modulation of F-spondin, particularly the inhibition of F-spondin, for increasing or stimulating bone formation and/or growth and mediating the alleviation of bone disease, disorders or conditions. The use of F-spondin, an active fragment thereof, or a modulator thereof for enhancing cartilage repair or preventing or treating cartilage degeneration, degenerative diseases or arthritic conditions is also provided. | 2010-01-21 |
20100015130 | DISC-1 PATHWAY ACTIVATORS IN THE CONTROL OF NEUROGENESIS - The invention relates to methods of treating neurological disorders in a subject, by activating a DISC1 pathway. Methods of promoting neurogenesis in adult neural progenitor cells, enhancing nerve generation and treating GSK3 disorders as well as related compositions are also provided. | 2010-01-21 |
20100015131 | Composition Comprising Antibodies to LINGO or Fragments Thereof - Endogenous LINGO-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-1 function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for LINGO-1, and methods of using such antibodies as antagonists of endogenous LINGO-1 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-LINGO-1 antibody | 2010-01-21 |
20100015132 | USES OF MAMMALIAN CYTOKINES AND AGONISTS; RELATED REAGENTS - Provided are methods of treatment for tumors. In particular, provided are methods of using of a cytokine molecule and its receptor. | 2010-01-21 |
20100015133 | Methods for Producing Polypeptides by Regulating Polypeptide Association - In the course of the present invention, it was discovered that one could regulate association between polypeptides by modifying amino acid residues that form the interface during the association to amino acids carrying the same type of charge. In this context, the present invention enables efficient formation of heterologous molecules. For example, the present invention can be suitably applied to the preparation of bispecific antibodies. | 2010-01-21 |
20100015134 | Therapy With CD4 Binding Peptides and Radiation - The present invention relates to a peptide, such as an antibody, capable of binding to CD4 and use thereof for the mediation of radiation treatment of a clinical condition. The radiation treatment may for instance by treatment with PUVA. | 2010-01-21 |
20100015135 | ANTI-EPHB4 ANTIBODIES AND METHODS USING SAME - The invention provides anti-EphB4 antibodies, and compositions comprising and methods of using these antibodies. | 2010-01-21 |
20100015136 | CAMPTOTHECIN-PEPTIDE CONJUGATES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME - The present invention relates to a novel compound of use in the improved delivery of therapeutic drug agents into target cells or tissues, composition comprising the same and uses thereof. The compound is more specifically a conjugate of a peptide moiety and a camptothecin, a derivative or analog thereof which provides numerous benefits, including enhancement in terms of aqueous solubility, pharmacokinetics and tissue distribution, enlargement of the therapeutic index, and limitation of the inter-patient metabolic variability, as well as improvement of delivery of the biologically active ingredient to the target cells or tissues. | 2010-01-21 |
20100015137 | RECEPTOR THAT BINDS TRAIL - A protein designated TRAIL receptor binds the protein known as TNF-Related Apoptosis-Inducing Ligand (TRAIL). The TRAIL receptor finds use in purifying TRAIL or inhibiting activities thereof. Isolated DNA sequences encoding TRAIL-R polypeptides are provided, along with expression vectors containing the DNA sequences, and host cells transformed with such recombinant expression vectors. Antibodies that are immunoreactive with TRAIL-R are also provided. | 2010-01-21 |
20100015138 | Crystal structure of Staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof - The present invention discloses crystal structure of | 2010-01-21 |
20100015139 | METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF - A method of inhibiting the adverse effects of alternative complement pathway activation products in a subject comprising administering to the subject an amount of anti-factor Ba antibody effective to selectively inhibit formation of an alternative complement pathway activation products C3a, C5a, and C5b-9, and activation of neutrophils, monocytes, and platelets. | 2010-01-21 |
20100015140 | Inhibitor Compounds and Cancer Treatment Methods - A synergistically effective combination of an anti-cancer agent and a therapeutic compound, such as an mTOR-Rictor complex inhibitor, a Serine 473 phosphorylation inhibitor, an AKT2 inhibitor, or a combination thereof, for use in the treatment of cancer, and methods and uses thereof. Also included are methods and uses of a thiosemicarbazone for treating a cancer in a mammal in need thereof characterized by over-expression of RAS, by an EGFR mutation, and/or by over-expression of AKT2. | 2010-01-21 |
20100015141 | 4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES - The invention relates to 4,6-disubstituted-1H-pyrazolo[3,4-d]pyrimidin-4-amine compounds, including 4-phenoxy-6-aryl-1H-pyrazolo[3,4-d]pyrimidine and N-aryl-6-aryl-1H-pyrazolo[3,4-d]pyrimidin-4-amine compounds of the Formula I: | 2010-01-21 |
20100015142 | METHODS FOR THE TREATMENT OF LADA AND OTHER ADULT- ONSET AUTOIMMUNE USING IMMUNOSUPPRESSIVE MONOCLONAL ANTIBODIES WITH REDUCED TOXICITY - The present invention provides methods of treating, preventing or ameliorating the symptoms of Latent Autoimmune Diabetes in Adults (LADA) and adult-onset type 1 diabetes through the use of anti-human CD3 antibodies. In particular, in invention provides methods of preventing or delaying insulin requirement in patients diagnosed with LADA. The methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor/alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the invention provides for modification of the anti-human CD3 antibodies such that they exhibit reduced or eliminated effector function and T cell activation as compared to non-modified anti-human CD3 antibodies. | 2010-01-21 |
20100015143 | Compositions and Methods Relating to Modulation of Immune System Components - A composition comprising a molecular blockade agent to a costimulatory molecule which costimulatory molecule satisfies the following criteria: a. absent in naÊve or resting T-lymphocytes; b. inducible; c. expressed; and d. prominent at the height of an immunopathological response, such as a disease/condition response. Preferably, the costimulatory molecule is OX40 and the molecular blockade agent is an antibody or antibody fragment having antibody activity to OX40. Further, the system may involve modulation of the molecular signal pathway of the aforesaid costimulatory molecule. | 2010-01-21 |
20100015144 | Methods for dosing an activin-actriia antagonist and monitoring of treated patients - In certain aspects, the present invention provides methods for dosing a patient with an activin-ActRIIa antagonist and methods for managing patients treated with an activin-ActRIIa anatagonist. In certain aspects, the methods involve measuring one or more hematologic parameters in a patient. | 2010-01-21 |
20100015145 | Use of a compound for reducing the biological effectiveness of IL-6 - Use of a compound comprising at least a structural entity which binds or is an antagonist for interleukin-6 (IL-6) and/or the IL-6 receptor or parts of it, preferably human IL-6 which compound depletes IL-6 from a solution or blocks at least one or more IL-6 functions on cell surfaces or in a solution for manufacturing of a medicament for the treatment or prevention of diseases selected from the group consisting of endothelial injury, destruction, increased risk for endothelial injury or destruction or immune disorders other than rheumatoid arthritis and combinations thereof. | 2010-01-21 |
20100015146 | TREATING DIABETES USING INHIBITORS OF IL-1 - The present invention describes a method of treating diabetes or metabolic syndrome with a compound that inhibits (a) IL-1, (b) the synthesis of IL-1, or (c) the release of IL-1. | 2010-01-21 |
20100015148 | METHODS AND COMPOSITIONS FOR THE UTILIZATION AND TARGETING OF OSTEOMIMICRY - A method for interfering with osteomimetic properties of a cell includes introducing into the cell an osteomimecry-interfering compound, wherein said osteomimecry-interfering compound prevents or ameliorates the expression of the osteomimetic properties of said cell. A method for treating or ameliorating an osteotropic-related cancer or disorder in a subject includes administering to the subject an osteomimecry interfering compound. A method for identifying a compound that modulates the osteomimetic potential of a cell includes contacting a cell exhibiting osteomimetic potential with a test compound; measuring expression levels of one or more osteomimetic gene products in the cell in the presence and in the absence of the test compound; and identifying a compound that modulates the osteomimetic potential, wherein the compound changes the expression levels of one or more osteomimetic gene products in the cell. | 2010-01-21 |
20100015149 | COMBINATION OF EPOTHILONE ANALOGS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES - Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders. | 2010-01-21 |
20100015150 | Tdf-related compounds and analogs thereof - The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders. | 2010-01-21 |
20100015151 | POLYPEPTIDES FROM NEISSERIA MENINGITIDIS - Various specific meningococcal proteins are disclosed. The invention provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by meningococcus, such as bacterial meningitis. | 2010-01-21 |
20100015152 | Diagnostic and therapeutic methods - The present invention provides the use of a protein found in breast, prostate, pancreatic and colon cancer cell membranes, known as BCMP 7, in the diagnosis, screening, treatment and prophylaxis of breast, prostate, pancreatic and/or colon cancer, as well as compositions comprising BCMP 7, including vaccines and antibodies that are immunospecific for BCMP 7. | 2010-01-21 |
20100015153 | Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells and Antibodies That Identify the Same - The invention relates to a novel compound termed NKp30 that is selectively expressed by all mature NK cells and that is involved in human natural cytoxicity as an activatory receptor, to new antibodies that bind to the NKp30 structure, and to the pharmaceutical and medicinal uses thereof. | 2010-01-21 |
20100015154 | IMMUNOGENIC MEMAPSIN 2 B-SECRETASE PEPTIDES AND METHODS OF USE - This application pertains to antibodies which specifically bind to immunogenic memapsin 2β-secretase peptides for use in the treatment of Alzheimer's disease and memapsin 2β-secretase disorders. The application also pertains to immunogenic compositions comprising memapsin 2β-secretase peptides and uses thereof. | 2010-01-21 |
20100015155 | PEGYLATED ABETA FAB - A method to treat conditions associated with Aβ peptide activity both prophylactically and therapeutically is described. The method employs humanized antibody fragments that specifically bind human Aβ peptide between amino acid positions 13-28, wherein the antibody fragments are covalently attached to a polyethylene glycol (PEG) molecule. | 2010-01-21 |
20100015156 | DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE IN CHILDREN - This invention provides methods of diagnosing and predicting disease progression of Crohn's disease. In one embodiment, a method of the invention is practiced by determining the presence or absence of CARD15 variants R702W, G908R, and/or 1007insC in a pediatric individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, and/or pANCA in a pediatric individual | 2010-01-21 |
20100015157 | ANTIBODY FORMULATIONS - The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab). | 2010-01-21 |
20100015158 | METHOD FOR TREATING ATROPHIC AGE RELATED MACULAR DEGENERATION - Compositions and methods for treating dry age related macular degeneration (dry AMD) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA). | 2010-01-21 |
20100015159 | Compositions and methods for treating kidney disease - The present invention relates to methods and compositions for the prevention and treatment of renal damage. The invention provides protein-based renal therapeutic agents for administration to subjects in order to prevent or treat renal degeneration or damage. | 2010-01-21 |
20100015160 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING ENDOMETRIOSIS - Although TF is expressed on perivascular cells of normal tissues and in the adventitial layer of blood vessels, these cells are sequestered from contact with circulating fVII by the tight endothelial cell layer of the normal vasculature. Therefore, differential expression of TF by endometriotic tissue makes it a specific target for inhibiting or treating endometriosis. Similarly, overexpression of PAR-2 by endometrial tissue in women with endometriosis makes it a target for inhibiting or treating endometriosis. In one embodiment, interference with binding of fVII to TF or of the TF/fVIIa to PAR-2 is accomplished by providing one or more antagonists that reduce or inhibit binding of these proteins as described above. In another embodiment, the catalytic activity of PAR-2 or the TF/fVIIa complex is inhibited by providing one or more antagonists as disclosed above. In another embodiment, TF and/or PAR-2 expression is downregulated by providing one or more inhibitory nucleic acids including, but not limited to, ribozymes, triplex-forming oligonucleotides (TFOs), antisense DNA, external guide sequences (EGSs)f siRNA, and microRNA specific for nucleic acids encoding TF or PAR-2. TF and PAR-2 antagonists can also be provided in combination with other anti-angiogenic agents or other agents used to treat endometriosis, such as those described above. | 2010-01-21 |
20100015161 | Composition Comprising In Vitro Expanded T-Lymphocytes and Vessel Formation Inhibitors Suitable in the Treatment of Cancer - Improved cancer therapy using a combination treatment with tumour-reactive T-lymphocytes obtained by an in vitro method for expansion and activation of tumour-reactive lymphocytes, in particular CD4+ helper and/or CD8+ T-lymphocytes and inhibitors of vessel formation inhibitors, notably inhibitors of VEGF. | 2010-01-21 |
20100015162 | Methods of Using Antibodies Against Human IL-22 - The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders. | 2010-01-21 |
20100015163 | DENDRITIC CELL POTENTIATION - A molecule capable of potentiating immune responses is described, as well as methods for using the molecule to enhance immune responses and enhance dendritic cell function. Also described are compositions containing the molecule and methods for using the compositions to treat or immunize individuals. | 2010-01-21 |
20100015164 | Compositions and Methods for Modulating Osteoblast Cell Differentiation and Bone Generation Through HIF-1a - The present invention provides a novel screening tool for the determination of compounds capable of promoting bone healing, promoting osteoblast cellular differentiation, improving bone mass or volume, and/or promoting osteogenesis that could be used in the treatment of various bone-loss or bone density decreasing disorders. The present invention also provides a screening tool for the determination of compounds capable of inhibiting osteoblast cellular differentiation, decreasing bone mass or volume, and/or inhibiting osteogenesis. Also provided are compositions and methods for the treatment of various bone-loss or bone density decreasing disorders. | 2010-01-21 |
20100015165 | Two Step Miniemulsion Process - The present invention is directed to a method of producing nanoparticles and nanoparticles obtainable by that method. The invention further relates to a pharmaceutical composition, comprising said nanoparticles and the use of the nanoparticles for the treatment of diseases and conditions, requiring a pharmaceutical agent to cross one or more physiological barriers. | 2010-01-21 |
20100015166 | Therapeutic antibodies - A pharmaceutical comprising a therapeutic protein that hinds to a therapeutic target, the protein being modified with a compound that inhibits binding of the protein to the therapeutic target, the modified protein being effective for reducing an immune response against the protein and for producing a therapeutic effect by binding to the therapeutic target. The therapeutic protein may be an antibody that includes an antibody combining site that binds to the therapeutic target. | 2010-01-21 |
20100015167 | COMPOSITIONS AND METHODS FOR IDENTIFYING AND TARGETING CANCER CELLS OF ALIMENTARY CANAL ORIGIN - Screening and diagnostic reagents, kits and methods for metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed. Compounds, compositions and methods of treating patients with metastatic colorectal cancer or stomach or esophageal cancer and for imaging metastatic colorectal cancer or stomach or esophageal tumors in vivo are disclosed. Compositions and methods for delivering active compounds such as drugs, gene therapeutics and antisense compounds to metastatic colorectal cancer or stomach or esophageal cells are disclosed. Vaccines compositions and methods of for treating and preventing metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed. | 2010-01-21 |
20100015168 | IMMUNOGENIC COMPOSITIONS FOR STREPTOCOCCUS AGALACTIAE - The invention relates to immunogenic polypeptides derived from epitopes in a Streptococcus agalactiae (“GBS”) protein GBS 80 and their use as prophylactic, diagnostic and therapeutic compositions. The invention also provides nucleic acids encoding the immunogenic polypeptides. Also provided are vectors useful for making such immunogenic polypeptides and host cells transformed with such vectors. In particular, the invention relates to a group immunogenic polypeptides derived from GBS 80. The compositions may include one or more of the immunogenic polypeptides either alone or with other antigenic components. For example, the immunogenic polypeptides may be combined with other GBS antigens to provide therapeutic compositions with broader range. In addition, the immunogenic polypeptides may also include flanking portions of the GBS 80 protein. | 2010-01-21 |
20100015169 | Tumor Antigens - Tumor antigen peptides that induce CTL from peripheral blood mononuclear cells of a patient with prostate cancer in an HLA-A2-restricted or an HLA-A24-restricted manner were identified based on the amino acid sequences of PSA, PSM, and PSCA, which are proteins known as markers of prostate cancer. Also disclosed is a peptide having a function as a tumor antigen that is recognized by HLA-A2-restricted CTL or HLA-A24-restricted CTL, an antibody against the peptide, a compound having interaction with the peptide, an agent for inducing CTL that includes the peptide, a pharmaceutical composition that includes one or more thereof, a method for identifying a compound that has interaction with the peptide, a method for inducing CTL using the peptide, a method for measuring the peptide and the antibody, as well as a reagent kit used for the identification method or the measurement method. | 2010-01-21 |
20100015170 | FLAGELLIN MUTANT VACCINE - The present invention provides a vaccine which effectively induces protective immune response particularly against flagellated pathogens (such as | 2010-01-21 |
20100015171 | VACCINES COMPRISING TB 10.4 - Vaccination with the combination of Ag85B-TB10.4 and IC31® adjuvant generated a high amount of polyfunctional CD4 | 2010-01-21 |
20100015172 | Method to reduce the physiologic effects of drugs on mammals - A method to reduce the physiologic effects of drugs in vivo by inducing specific anti-drug antibodies using drugs conjugated to carrier molecules so as to reduce a drug's toxicity and its physiologic effects upon the recipient. This method includes the treatment and prophylactic prevention of drug abuse, specifically for cocaine and nicotine, and to help reduce the toxic effects of drugs, such as anti-neoplastics. | 2010-01-21 |
20100015173 | COILED-COIL LIPOPEPTIDE HELICAL BUNDLES AND SYNTHETIC VIRUS-LIKE PARTICLES - The invention relates to lipopeptide building blocks consisting of a peptide chain comprising a coiled-coil domain, linked covalently to a lipid moiety comprising long alkyl or alkenyl chains, and optionally linked to an antigen; and to helical lipopeptide bundles and synthetic virus-like particles formed by aggregation. The nanometer size and shape of these bundles and particles, their stability under aqueous physiological conditions, their chemical composition, the possibility to incorporate B- and T-cell epitopes, and their production by chemical synthesis, make them highly suitable as vaccine delivery vehicles. | 2010-01-21 |
20100015174 | METHOD TO CONTROL DENGUE VIRUSES IN HUMANS BY PICOLINIC ACID AND DERIVATIVES THEREOF - A method treats and then prevents a virus for afflicting an animal or a human as a metalloprotein mediates the virus. The method administers systemically a therapeutic pharmacological agent of picolinic acid either singly or with interferons, chemokines or cytokines to fight dengue fever virus. The picolinic acid inactivates the metalloprotein that allows replication of the virus. The picolinic acid has the structure of: | 2010-01-21 |
20100015175 | Vaccine - The invention relates to a vaccine for the treatment of disease caused by | 2010-01-21 |
20100015176 | Settings for recombinant adenoviral-based vaccines - The present invention provides new uses of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, the invention provides new assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting. | 2010-01-21 |
20100015177 | Method for Preserving Viral Particles - A method for preserving viral particles comprises: (i) providing an aqueous solution of one or more sugars, a polyethyleneimine and said viral particles wherein the concentration of polyethyleneimine is 15 μM or less based on the number-average molar mass (M | 2010-01-21 |
20100015178 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE - The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives. | 2010-01-21 |
20100015179 | Attenuation of encephalitogenic alphavirus and uses thereof - The present invention is drawn to generating attenuated and less cytopathic forms of New World alphaviruses that can be used in immunogenic compositions as vaccines against both Old and New World alphaviruses. In this regard, the present invention discloses that the N-terminal, ˜35-aa-long peptide of VEEV, EEEV and, most likely, of WEEV capsid proteins plays the most critical role in the downregulation of cellular transcription and development of cytopathic effect. The identified, VEEV-specific peptide, C | 2010-01-21 |
20100015180 | Stabilizer and Vaccine Composition Comprising One or More Live Attenuated Flaviviruses - The present invention relates to stabilizers for compositions, including immunogenic compositions, such as vaccine compositions, comprising one or more live attenuated flaviviruses, to bulk vaccine compositions stabilized with these stabilizers, particularly dry vaccine compositions prepared from these bulk vaccine compositions, and to methods for stabilizing one or more live attenuated flaviviruses. | 2010-01-21 |
20100015181 | Vaccine formulation - Spore coat-associated proteins from members of | 2010-01-21 |
20100015182 | COCCIDIOSIS VACCINES - The present invention discloses a vaccine that provides protection from coccidiosis, and methods of making and using the vaccine alone, or in combination with other protective agents. | 2010-01-21 |